http___bg.gsk.com_bg-bg__D0_B7_D0_B0-_D0_BD_D0_B0_D1_81__D0_BF_D0_BE_D0_BB_D0_B8_D1_82_D0_B8_D0_BA_D0_B8-_D0_BF_D1_80_D0_B0_D0_B2_D0_B8_D0_BB_D0_BD_D0_B8_D1_86_D0_B8-_D0_B8-_D1_81_D1_82_D0_B0_D0_BD_D0_B4_D0_B0_D1_80_D1_82_D0_B8__1.xml
1.1 2.1 3.1 4.1 5.1 6.1 7.1 8.1 9.1 10.1 10.2
Политики, правилници и стандарти Кодексът за поведение на GSK, политиките и стандартите, представят основните принципи, които ни водят към правилното взаимодействие с медицинските специалисти, партньори, контрагенти, държавните органи и обществото като цяло. GSK кодекс за поведение - Нашият Code of Conduct - Code of Practice for Promotion and Scientific Engagement (prescription medicines) Anti-Bribery and Corruption (ABAC) Програма Anti-Bribery and Corruption (ABAC) Програмата има за цел да помогне за поддържане на високите етични стандарти на компанията, както и да представи основните антикорупционни принципи и начини на работа. АВАС Програмата включва съвети за поведение, избягване на ситуации с потенциален риск от корупция, както и реални примери за компании, засегнати от корупционни практики. Насоки за трети страни по Anti-Bribery and Corruption (ABAC) Програма Насоките включени в Anti-Bribery and Corruption (ABAC) Програмата се предоставят на всички бизнес партньори, доставчици и контрагенти, с които ГлаксоСмитКлайн се ангажира. Целта е да ги запознаем с антикорупционната ни политика и с очакванията, които имаме към тях като наши бизнес партньори.
1.1 2.1 3.1 4.1 5.1 6.1 6.2 7.1 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1 19.1 20.1 21.1 22.1 23.1 24.1 25.1 26.1 27.1 28.1 29.1 30.1 31.1 32.1 33.1 34.1 35.1 36.1 37.1 38.1 39.1 40.1 41.1 42.1 43.1 44.1 45.1 46.1 47.1 48.1 49.1 50.1 51.1 52.1 53.1 54.1 55.1 56.1 57.1 58.1 59.1 60.1 61.1 62.1 63.1 64.1 65.1 66.1 67.1 68.1 69.1 70.1 71.1 72.1 73.1 74.1 75.1 76.1 77.1 78.1 79.1 80.1 80.2 81.1 81.2 82.1 83.1 83.2 83.3
Policies, codes and standards Codes of conduct GSK Code of Conduct Anti-Bribery and Corruption (ABAC) Programme Anti-Bribery and Corruption Programme Handbook The Anti-Bribery and Corruption (ABAC) Programme is part of GSK’s response to the threat and risk of bribery and corruption. The programme includes the ABAC Handbook, which has been designed to assist internal and external parties understand corruption risk and identify people’s responsibilities to actively combat both real and perceived corruption. - GSK Anti-Bribery and Corruption Handbook - GSK Policy on Preventing Corrupt Practices and Maintaining Standards of Documentation Anti-Bribery and Corruption Programme Third Party Guidelines Third Party Guidelines are provided to all third parties that GSK engages with in order to make them aware of our anti-bribery and corruption policies and what we expect from them as our business partners Public policies GSK access and developing countries - Developing world vaccine production technology transfer - IP and access to medicines in developing countries - Technology transfer, capacity building and developing countries - Non-communicable diseases and the developing world - The post 2015 development agenda - Universal healthcare coverage - Civil society organisations and vaccine procurement - Working together for the health of mothers and children GSK and research & development - Clinical trials in the developing world - Incentivising antibacterial R&D - Cloning technologies and stem cell research - The convention on biological diversity - Disclosure of clinical trial information - The care, welfare and treatment of animals - The role of transgenic animals in biomedical research - Use of Non-human Primates (NHPs) in the Discovery and Development of Medicines and Vaccines GSK and intellectual property - Incremental innovation - Compulsory licences - Evergreening - Proposals for a disclosure in patent applications - Regulatory data protection GSK and the environment - Hazardous chemical management - Genetically modified micro-organisms and Environment, Health and Safety (EHS) - GSK and REACH - Nanotechnology - Ozone depletion and metered-dose inhalers for asthma - Pharmaceuticals in environment - The impact of climate change on health - Use of ozone depleting substances in ancillary plant and equipment GSK and public health - Counterfeiting of healthcare products - Pharmacovigilance - Paediatric medicines - Tiered pricing & vaccines - Pandemic preparedness - Information to patients GSK and other issues - Conflict minerals - Competitiveness and investment criteria - Approach to pricing - Human rights - Marketing practices - Product donations - Corporate binding rules Other reports GlaxoSmithKline plc - Specialised Disclosure Report GlaxoSmithKline Capital plc Euro Medium Term Note Programme - GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2014 - GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2013 - GlaxoSmithKline Euro Medium Term Note Programme – Registration Document - GlaxoSmithKline Euro Medium Term Note Programme - Supplementary Prospectus Document GlaxoSmithKline Capital plc Annual Reports - 2014 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc - 2013 Annual Report GlaxoSmithKline Capital plc - 2013 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc - 2012 Annual Report GlaxoSmithKline Capital plc - 2012 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc - 2011 Annual Report GlaxoSmithKline Capital plc - 2011 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc - 2010 Annual Report GlaxoSmithKline Capital plc - 2009 Annual Report GlaxoSmithKline Capital plc - 2008 Annual Report GlaxoSmithKline Capital plc UK Pension Schemes Statements of Investment Principles (SIP) The links below will allow you to download the Statements of Investment Principles for the four main UK pension schemes. The contents of these documents are set out under UK law and cover the investment policies of the schemes in the following broad areas: Risk Measurement and Management, Implementation and Governance. The documents also provide details of the asset allocation of the investments. The Statements have been agreed by the Trustee Boards on the basis of written advice from their appointed external investment advisers and lawyers. There is a consultation process on the SIP with the participating employers as required by law. The Statements are reviewed by the Trustees annually and also if there are any significant changes to the investment policies. The Trustees monitor compliance with this statement at least annually. Fund manager activity is reviewed quarterly through reports prepared by investment consultants. Additionally, meetings are held with fund managers at least annually to review the activities and compliance with their contractual terms and with the Statements of Investment Principles.